Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

A sick child taking medication Real-world data on use of RAAS inhibitors can be used to support future pragmatic studies to optimize management of childhood-onset SLE, according to investigators.

In this rapidly evolving setting, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their ...